Should I buy or sell Cytek Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTKB shares. View CTKB analyst ratings or view top-rated stocks .

What is Cytek Biosciences' stock price target for 2024?

4 analysts have issued 12-month price objectives for Cytek Biosciences' stock. Their CTKB share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.33 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price. View analysts price targets for CTKB or view top-rated stocks among Wall Street analysts .

How have CTKB shares performed in 2023?

Cytek Biosciences' stock was trading at $10.21 at the start of the year. Since then, CTKB stock has decreased by 27.3% and is now trading at $7.42. View the best growth stocks for 2023 here .

Are investors shorting Cytek Biosciences?

Cytek Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 8,380,000 shares, an increase of 5.8% from the October 31st total of 7,920,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 7.8 days. Currently, 7.2% of the shares of the company are short sold. View Cytek Biosciences' Short Interest .

When is Cytek Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our CTKB earnings forecast .

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.02. The business had revenue of $48 million for the quarter, compared to analyst estimates of $55.09 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.73% and a negative net margin of 7.61%.

What ETF holds Cytek Biosciences' stock ?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.

When did Cytek Biosciences IPO?

(CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Cytek Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (4.99%), New York State Common Retirement Fund (1.72%), Wellington Management Group LLP (1.07%), Northern Trust Corp (0.84%), Charles Schwab Investment Management Inc. (0.61%) and Bank of New York Mellon Corp (0.61%). Insiders that own company stock include Jack Ball, Ming Yan , Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang . View institutional ownership trends .

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cytek Biosciences Stock Price, News & Analysis (NASDAQ:CTKB)

$7.42

+0.06 (+0.82%)

(As of 12/5/2023 ET)

Compare

Today's Range: $7.22
▼
$7.48
50-Day Range: $4.10
▼
$7.42
52-Week Range: $3.80
▼
$13.77

Volume: 1.08 million shs
Average Volume: 1.01 million shs
Market Capitalization: $1.01 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.33

Cytek Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 39.3% Upside
$10.33 Price Target
Short Interest: Bearish
7.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$730,400 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.12) to ($0.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

706th out of 948 stocks

Analytical Instruments Industry

18th out of 27 stocks

3.3

Analyst's Opinion

Consensus Rating
Cytek Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.33, Cytek Biosciences has a forecasted upside of 39.3% from its current price of $7.42.
Amount of Analyst Coverage
Cytek Biosciences has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.21% of the float of Cytek Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Cytek Biosciences has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in Cytek Biosciences has recently increased by 5.81%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cytek Biosciences does not currently pay a dividend.
Dividend Growth
Cytek Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CTKB.

2.1

News and Social Media Coverage

News Sentiment
Cytek Biosciences has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.
Search Interest
7 people have searched for CTKB on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
MarketBeat Follows
2 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cytek Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $730,400.00 in company stock.
Percentage Held by Insiders
15.90% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.50% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cytek Biosciences are expected to grow in the coming year, from ($0.12) to ($0.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cytek Biosciences is -74.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cytek Biosciences is -74.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cytek Biosciences has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cytek Biosciences Stock (NASDAQ:CTKB)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CTKB Stock News Headlines

November 28, 2023 | americanbankingnews.com

Patrik Jeanmonod Sells 3,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock

November 22, 2023 | finance.yahoo.com

Insider Sell Alert: CTO Ming Yan Sells 20,000 Shares of Cytek Biosciences Inc (CTKB)

December 6, 2023 | Edge On The Street (Ad)

The Battery Metal Nobody Told You About

According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."

November 16, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Cytek Biosciences (CTKB), DENTSPLY SIRONA (XRAY)

November 14, 2023 | finance.yahoo.com

Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference

November 12, 2023 | finance.yahoo.com

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

Cytek Biosciences Inc (CTKB) Q3 2023 Earnings Report Summary

November 8, 2023 | finance.yahoo.com

Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’

December 6, 2023 | Edge On The Street (Ad)

Energy Storage Trend Ignites Frenzy Over Vanadium Supply

As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.

November 7, 2023 | msn.com

Cytek Biosciences GAAP EPS of -$0.05 misses by $0.08, revenue of $48M misses by $7.48M

November 7, 2023 | finance.yahoo.com

Cytek Biosciences Reports Third Quarter 2023 Financial Results

October 31, 2023 | finance.yahoo.com

Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q3 Earnings Expected to Decline

October 24, 2023 | markets.businessinsider.com

Morgan Stanley Maintains Equal-Weight Rating for Cytek Biosciences: Here's What You Need To Know

October 19, 2023 | finance.yahoo.com

Cytek Biosciences to Report Third Quarter 2023 Financial Results on November 7, 2023

October 12, 2023 | finance.yahoo.com

Insider Sell: Cytek Biosciences Inc President and CEO Wenbin Jiang Sells 20,000 Shares

September 27, 2023 | finance.yahoo.com

Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters

September 21, 2023 | benzinga.com

Massive Insider Trade At Cytek Biosciences

September 21, 2023 | finance.yahoo.com

Insider Sell: CTO Ming Yan Sells 20,000 Shares of Cytek Biosciences Inc

September 20, 2023 | finance.yahoo.com

Cytek Biosciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

September 20, 2023 | finance.yahoo.com

Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe

September 9, 2023 | finance.yahoo.com

Insider Sell: Cytek Biosciences Inc CEO Wenbin Jiang Sells 20,000 Shares

September 6, 2023 | finance.yahoo.com

Cytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 4, 2023 | finance.yahoo.com

With 56% institutional ownership, Cytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst the big guns

August 28, 2023 | finance.yahoo.com

Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services

August 10, 2023 | finance.yahoo.com

Cytek Biosciences to Participate in the UBS MedTech, Tools and Genomics Summit

August 9, 2023 | finance.yahoo.com

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Lag Estimates

August 8, 2023 | finance.yahoo.com

Cytek Biosciences Reports Second Quarter 2023 Financial Results

See More Headlines

Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CTKB
CUSIP: N/A
CIK: 1831915
Web: www.cytekdev.com
Phone: 877-922-9835
Fax: N/A
Employees: 688
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.33
High Stock Price Target: $14.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +39.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $2.58 million
Net Margins: -7.61%
Pretax Margin: -8.58%
Return on Equity: -1.73%
Return on Assets: -1.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.20
Quick Ratio: 6.06

Sales & Book Value

Annual Sales: $183.12 million
Price / Sales: 5.49
Cash Flow: $0.08 per share
Price / Cash Flow: 98.64
Book Value: $3.16 per share
Price / Book: 2.35

Miscellaneous

Outstanding Shares: 135,549,000
Free Float: 113,997,000
Market Cap: $1.01 billion
Optionable: Not Optionable
Beta: 1.32

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Wenbin Jiang Ph.D. (Age 59)
President, CEO & Chairman of the Board
Comp: $964.21k
Dr. Ming Yan Ph.D. (Age 60)
CTO & Director
Comp: $616.26k
Ms. Valerie T. Barnett J.D. (Age 48)
General Counsel & Corporate Secretary
Comp: $535.98k
Mr. Patrik Sebastian Jeanmonod (Age 57)
Chief Financial Officer
Comp: $412.54k
Mr. Chris Williams (Age 54)
Chief Operating Officer
Mr. Paul D. Goodson
Head of Investor Relations
Dr. Allen B. Poirson Ph.D. (Age 63)
Senior Vice President of Business & Corporate Development
Dr. Philippe Busque Ph.D.
Senior Vice President of Global Sales & Services
Ms. Connie Wedel
Chief People Officer
Mr. Melik Ulusu
Senior Vice President of Operations & Integrated Supply Chain

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CTKB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTKB shares.
View CTKB analyst ratings or view top-rated stocks.
What is Cytek Biosciences' stock price target for 2024?: 4 analysts have issued 12-month price objectives for Cytek Biosciences' stock. Their CTKB share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.33 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price.
View analysts price targets for CTKB or view top-rated stocks among Wall Street analysts.
How have CTKB shares performed in 2023?: Cytek Biosciences' stock was trading at $10.21 at the start of the year. Since then, CTKB stock has decreased by 27.3% and is now trading at $7.42.
View the best growth stocks for 2023 here.
Are investors shorting Cytek Biosciences?: Cytek Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 8,380,000 shares, an increase of 5.8% from the October 31st total of 7,920,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 7.8 days. Currently, 7.2% of the shares of the company are short sold.
View Cytek Biosciences' Short Interest.
When is Cytek Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CTKB earnings forecast.
How were Cytek Biosciences' earnings last quarter?: Cytek Biosciences, Inc. (NASDAQ:CTKB) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.02. The business had revenue of $48 million for the quarter, compared to analyst estimates of $55.09 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.73% and a negative net margin of 7.61%.

What ETF holds Cytek Biosciences' stock ?: First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.
When did Cytek Biosciences IPO?: (CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.
Who are Cytek Biosciences' major shareholders?: Cytek Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (4.99%), New York State Common Retirement Fund (1.72%), Wellington Management Group LLP (1.07%), Northern Trust Corp (0.84%), Charles Schwab Investment Management Inc. (0.61%) and Bank of New York Mellon Corp (0.61%). Insiders that own company stock include Jack Ball, Ming Yan, Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang.
View institutional ownership trends.
How do I buy shares of Cytek Biosciences?: Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CTKB) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial